Stay updated with breaking news from Stringent Regulatory Authorization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Russia's role in the war dominated the addresses of the US president and Japan PM. Predictably, Modi did not comment on Ukraine or Russia in his opening remarks.
India could have a fourth Covid vaccine by August with Hyderabad-based Biological E’s candidate having completed its phase one and two trials and about to enter stage three, V K Paul, member-health, NITI Aayog, told reporters on Wednesday. Besides, Covishield and Covaxin, which are available in India, regulator Drugs Controller General of India (DCGI) has also approved Russia’s Sputnik V. Paul said that the vaccine was being developed with the help of the department of biotechnology and the company has a capacity to make around 70 million doses per month. “It is a significant developmen...
Quad officials hail vaccine initiative for 2022 Updated: Updated: The logistics being worked out Share Article AAA Quad countries plans to provide 1 billion doses of COVID-19 vaccines to Southeast Asian countries by 2022. | Photo Credit: RAFIQ MAQBOOL The logistics being worked out The vaccine initiative announced by the Quad leaders last week was a “path-breaking effort” at a “truly historic” summit, said Minister of State for External Affairs V. Muraleedharan, as officials in the Australia-India-Japan-U.S. coalition also said that details of the plan to provide 1 billion dos...
Quad partners are aiming to distribute the vaccines in Southeast Asia where China is already distributing its own version.
Share Hyderabad: The US International Development Finance Corporation (DFC), America’s development bank, will work with the Hyderabad-based Biological E and finance its increased capacity to further the company’s endeavour to produce 1 billion doses of Covid-19 vaccine by the end of 2022. Though DFC did not specify how much money it will invest in Biological E, it stated that it will invest between $5 million to $500 million per eligible project from the private sector to support the manufacture of vaccines. “It is hard to conceive of an investment with a greater developmental impact th...